Galectin Therapeutics Inc Dossier - Source-backed chat

Galectin Therapeutics Inc

GALTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.57

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.76Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $379.2M

Shares Outstanding 100.8M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Galectin Therapeutics is a clinical-stage biotechnology company focused on developing its lead galectin-3 inhibitor, belapectin, for MASH cirrhosis and portal hypertension. While the Phase 2b NAVIGATE trial missed its composite primary endpoint in the intent-to-treat population, robust secondary analyses and per-protocol data (showing a 49.3% reduction in new varices for the 2 mg/kg cohort) provide strong biological validation. The company is actively engaging with the FDA in Q2 2026 to align on a regulatory path forward. However, with a cash runway extending only through May 2027 and substantial related-party convertible debt, the company faces significant dilution and financing risks, making a Hold recommendation appropriate until regulatory clarity and strategic partnerships are established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$11.00

Mean target$11.00

High · most bullish analyst$11.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The FDA requires a large, lengthy, and expensive Phase 3 trial that Galectin cannot afford without massive equity dilution. Strategic partnership discussions stall, forcing the company to heavily rely on its ATM program at depressed share prices, severely diluting existing shareholders.

Base CaseCentral scenario

The FDA aligns on a clear Phase 3 trial design for the 2 mg/kg belapectin dose in a targeted patient population (e.g., per-protocol or U.S. subgroups). Galectin secures a strategic partner to co-fund the late-stage development, extending its cash runway and mitigating dilution. The stock stabilizes as clinical execution resumes.

Bull CaseUpside scenario

The bull case for Galectin Therapeutics centers on its lead candidate, belapectin (a galectin-3 inhibitor), which has achieved alignment with the FDA on a single, well-controlled Phase 3 trial design for treating MASH (Metabolic Dysfunction-Associated Steatohepatitis) cirrhosis with portal hypertension. This regulatory alignment significantly de-risks the clinical development path, clarifies endpoints, and shortens commercialization timelines. Furthermore, because there are currently no approved therapies that prevent the progression of MASH cirrhosis with portal hypertension, a successful Phase 3 trial and subsequent approval would allow belapectin to capture a massive, open market. Positive biomarker data from the NAVIGATE Phase 2b trial's 36-month completers also provides strong clinical support to attract strategic pharmaceutical partnerships.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong biological and mechanistic validation of belapectin 2 mg/kg, supported by significant reductions in key biomarkers of fibrogenesis (PRO-C3, YKL-40) and portal hypertension.
Statistically significant 49.3% reduction in new varices in the pre-specified per-protocol population (n=287) and 68.1% reduction in the U.S. completer subgroup.
Favorable safety and tolerability profile of belapectin, with adverse event rates comparable to placebo over 18 months of treatment.
Financial backing from the Chairman of the Board, including an available $10 million line of credit to support near-term operations.

Key Investment Risks

High clinical and regulatory risk, as the primary composite endpoint of the NAVIGATE trial was missed in the intent-to-treat population.
Limited cash runway extending only through May 2027, requiring substantial additional capital to fund future late-stage clinical trials.
Significant potential for equity dilution from the $32.5 million ATM program and outstanding convertible debt/derivative liabilities.
Heavy reliance on a single clinical candidate (belapectin), with limited pipeline diversification.

Thesis Invalidation Triggers

FDA refusal to accept the per-protocol or subgroup analyses as a basis for designing a registrational Phase 3 trial.
Inability to secure a strategic partner or alternative non-dilutive financing by early 2027.
Safety signals or unexpected adverse events emerging from the ongoing 36-month extended treatment analyses.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.